MAZE Maze Therapeutics, Inc.
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Maze Therapeutics, Inc. (MAZE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Phase 2 trial of MZE829 initiated Nov 2024; topline proof of concept data expected Q1 2026—triggered by recent clinical progress
- • Material update: Net loss $96.6M 9M 2025 vs net income $81.8M 9M 2024; accumulated deficit $455.0M due to increased R&D and operational costs
Get deeper insights on Maze Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.